Setup, so nobody has to ask: orforglipron · two weeks · 37 °C.
I am trying to build something sustainable rather than something thorough that I will abandon.
I have already decided the broad direction; this is about the specifics.
How would you structure this, and what thresholds would you set in advance?
If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
| Δ mass (Da) | Most likely cause | Distinguishing feature |
|---|---|---|
| +1 | Deamidation (Asn or Gln) | New peak, slightly earlier retention |
| −17 | Loss of ammonia | Often with deamidation |
| −18 | Dehydration / succinimide | pH-dependent, reversible |
| +16 | Oxidation (Met, Trp) | Earlier retention, light-related |
| −128 | Missing Gln or Lys | Deletion sequence from synthesis |
| 0 | Isomer: racemisation or scrambling | Same mass, shifted retention |
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
Assume segregation is possible, and design your sampling to catch it if it exists.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemTwo vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
To be exact about it, if you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.